Filed Pursuant to Rule 424(b)(5)
Registration No. 333-269631
Registration No. 333-269631
(To Prospectus dated February 14, 2023)
Up to $3,614,170
BioRestorative Therapies, Inc.
Common Stock
___________________________
We have entered into an At The Market Offering Agreement, or the Sales Agreement, with Rodman & Renshaw LLC, or the Agent, relating to the sale of
shares of our common stock, par value $0.0001 per share, or the common stock, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock
having an aggregate offering price of up to $3,614,170 from time to time through or to the Agent acting as sales agent or principal, at our discretion.
Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus will be made in sales deemed to be “at the market
offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including without limitation sales made directly on or through the Nasdaq Capital Market, or Nasdaq, or any other existing trading
market in the United States for our common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to the Agent as principal in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices or in any other method permitted by law. The Agent is not required to sell any number or dollar amount of our common stock but will act as a sales agent and use commercially reasonable efforts to sell
on our behalf all of the common stock requested to be sold by us, consistent with its normal trading and sales practices and subject to the terms and conditions set forth in the Sales Agreement. There is no arrangement for funds to be received in any
escrow, trust or similar arrangement.
We will pay the Agent commissions for its services in acting as agent in the sale of our common stock. The
Agent will be entitled to compensation at a commission rate equal to 3.0% of the aggregate gross sales price of the shares sold. In connection with the sale of our common stock on our behalf, the Agent will be deemed to be an “underwriter” within
the meaning of the Securities Act and the compensation of the Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Agent with respect to certain liabilities,
including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. This
offering pursuant to this prospectus supplement will terminate upon the earlier of (1) the sale of common stock pursuant to this prospectus supplement having an aggregate sales price of $3,614,170 and (2) the termination by us or the Agent of the
Sales Agreement pursuant to its terms.
Our common stock is listed on Nasdaq under the symbol “BRTX.” The last reported sales price of our shares of common stock on October 31, 2024 was $1.56 per
share.
The aggregate market value of our outstanding common stock held by non-affiliates, or the public float, as of the date hereof pursuant to General
Instruction I.B.6. of Form S-3, is approximately $10,842,510, which was calculated based upon 5,647,141 shares of our outstanding common stock held by non-affiliates at a price of $1.92 per share, the closing price of our common stock on September
20, 2024 (which was the highest closing sale price of our common stock on Nasdaq within 60 days prior to the date hereof).
Accordingly, based on our public float of $10,842,510 as of the date hereof, and in accordance with General Instruction I.B.6 of Form S-3, we may sell our
securities in a public primary offering with a value not to exceed $3,614,170 (which is less than one-third of our public float) in any 12 calendar month period. We have not sold any securities pursuant to General Instruction I.B.6 of Form S-3
during the 12 calendar months prior to and including the date of this prospectus supplement. Therefore, we may currently offer and sell shares of our common stock having an aggregate offering price of up to $3,614,170 in any 12 calendar month period
from time to time through or to the Agent in accordance with the Sales Agreement.
Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding more than
one-third of our public float in any 12-month period so long as our public float remains below $75 million.
___________________________
Investing in our common stock involves risks. See the section entitled
“Risk Factors” beginning on page S-7 of this prospectus supplement, page 4 of the accompanying
prospectus and under similar headings in the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement and
the accompanying prospectus. Any representation to the contrary is a criminal offense.
___________________________
Rodman & Renshaw LLC
The date of this prospectus supplement is November 6, 2024
TABLE OF CONTENTS
|
Page
|
|
This document contains two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and
also supplements and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus, which
provides more general information, some of which may not apply to this offering. If the information contained in this prospectus supplement differs or varies from the information contained in the accompanying prospectus, you should rely on the
information set forth in this prospectus supplement.
You should rely only on the information contained or incorporated by reference into this prospectus supplement and the accompanying
prospectus. We have not, and the Agent has not, authorized anyone else to provide you with information that is in addition to or different from that contained or incorporated by reference into this prospectus supplement and the accompanying
prospectus, along with the information contained in any permitted free writing prospectuses we have authorized for use in connection with this offering.
We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are
permitted. The information contained in this prospectus supplement and the accompanying prospectus is accurate only as of the date of this prospectus supplement or the date of the accompanying prospectus, and the information in the documents
incorporated by reference into this prospectus supplement and the accompanying prospectus is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus
or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since those dates. It is important for you to read and consider all information contained or incorporated by reference into
this prospectus supplement and the accompanying prospectus in making your investment decision. You should read both this prospectus supplement and the accompanying prospectus, as well as the documents incorporated by reference into this prospectus
supplement and the accompanying prospectus and the additional information described under “Where You Can Find More Information” in this prospectus supplement and in the accompanying prospectus, before investing in our common stock.
Unless the context of this prospectus supplement indicates otherwise, the terms “BioRestorative,” the “Company,” “we,” “us” or “our”
refer to BioRestorative Therapies, Inc. and its subsidiaries.
S-1
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights certain information about us and this offering. Because it is a summary, it does not contain all of the
information that you should consider before investing. Before investing in our common stock, you should read this entire prospectus supplement and the accompanying prospectus carefully, including the “Risk Factors,” and the financial statements
and accompanying notes thereto and other information and documents incorporated by reference into this prospectus supplement and the accompanying prospectus.
Our Company
We develop therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. As described below, our
two core programs relate to the treatment of disc/spine disease and metabolic disorders. We also offer biocosmeceutical products as discussed below.
|
●
|
Disc/Spine Program (brtxDisc). Our
lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells, or MSCs,
collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the
bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The
treatment is intended for patients whose pain has not been alleviated by non-surgical procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration, or the FDA, to
commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have commenced such
clinical trial through the execution of a CRO agreement with PRC Clinical, the execution of clinical trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the
expansion of our laboratory to include capabilities for clinical production. In March 2022, a United States patent related to our Disc/Spine Program was
issued. We have been granted certain exclusive license rights with regard to the patent.
|
|
●
|
Metabolic Program (ThermoStem). We
are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells, or BADSC, to generate brown adipose tissue, or BAT. We refer to this as our ThermoStem Program. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical
research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may
have a reduced risk for obesity and diabetes. Patents related to the ThermoStem Program have been issued in the United States and other
jurisdictions.
|
S-2
|
●
|
BioCosmeceuticals. We operate a
commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This
proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of
expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering FDA approvals in the emerging
biocosmeceuticals space.
|
We have also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or
material to the spine and discs (and other parts of the body). We anticipate that FDA approval or clearance will be necessary for this device prior to commercialization. We do not intend to utilize this device in connection with our Phase 2
clinical trial with regard to BRTX-100.
Preliminary Estimated Financial Data as of September 30, 2024
Based on the information and data currently available, as of September 30, 2024, we had approximately $1.5 million of cash and
$11.6 million in investments held in marketable securities.
The preliminary estimate above represents the most current information available to our management and does not present all
necessary information for an understanding of our financial condition as of September 30, 2024. This is a preliminary estimate which should not be regarded as a representation by us or our management as to our actual financial condition as of
September 30, 2024. Additional information and disclosures would be required for a more complete understanding of our financial position as of September 30, 2024 and our results of operations for the three and nine months then ended.
Our final data may vary from the information herein. Prospective investors should not place undue reliance on the estimate, and
this information should not be viewed as a substitute for our full interim or annual financial statements prepared in accordance with U.S. generally accepted accounting principles. Further, this estimate is not necessarily indicative of our
cash position to be expected at the end of the year or any future period. See the sections titled “Risk Factors,” and “Special Cautionary Note Regarding Forward-Looking Statements,” in this prospectus supplement, the accompanying prospectus,
and under similar headings in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for additional information regarding factors that could affect our cash position and results in future
periods.
The preliminary cash position and investments held in marketable securities as of September 30, 2024 set forth above has been
prepared by, and is the responsibility of, management. Marcum LLP, our independent registered public accounting firm, has not reviewed such preliminary data as of September 30, 2024.
S-3
Corporate Information
We are a Nevada corporation. Our headquarters are located at 40 Marcus Drive, Suite One, Melville, New York 11747. Our telephone number is (631)
760-8100. We maintain certain information on our website at www.biorestorative.com. The information on our website is not (and should not be considered) part of this prospectus supplement and is not incorporated into this prospectus
supplement by reference. We have included our website address solely as an inactive textual reference. Investors should not rely on any such information in deciding whether to purchase our common stock.
S-4
THE OFFERING
|
Common stock offered
|
Shares of our common stock having an aggregate offering price of up to $3,614,170.
|
|
Shares of common stock to be outstanding immediately after this offering(1)
|
Up to 9,236,694 shares, assuming sales of 2,316,775 shares of common stock in this offering at an assumed offering price of $1.56 per share, which was the
closing price of our common stock on Nasdaq on October 31, 2024. The actual number of shares issued will vary depending on the sales price at which shares may be sold from time to time during this offering.
|
|
Manner of offering
|
“At the market offering” as defined in Rule 415(a)(4) under the Securities Act, that may be made from time to time on Nasdaq, the existing trading market for
our common stock, through the Agent as sales agent or principal. See “Plan of Distribution” on page S-15 of this prospectus supplement.
|
|
Use of proceeds
|
We intend to use the net proceeds from this offering in connection with our clinical trials with respect to BRTX-100,
pre-clinical research and development with respect to our ThermoStem Program and for general corporate purposes and working capital. We may also use a portion of the net proceeds from this
offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to do so. See “Use of Proceeds”
on page S-13 of this prospectus supplement.
|
|
Risk factors
|
See “Risk Factors” beginning on page S-7 of this prospectus supplement, and under similar headings in other documents incorporated by
reference into this prospectus supplement and the accompanying prospectus, for a discussion of factors you should consider carefully before deciding to invest in our common stock.
|
|
Nasdaq Capital Market symbol
|
“BRTX”
|
(1) Based on 6,919,919 shares of common stock outstanding as of October 31, 2024, and excludes the following securities as of such date: (i)
outstanding warrants to purchase up to 3,951,670 shares of our common stock at a weighted exercise price of $3.68 per share, (ii) outstanding options to purchase up to 3,401,608 shares of our common stock at a weighted exercise price of $2.60
per share,
S-5
(iii) 1,398,158 shares of Series B preferred stock convertible into an equal number of shares of common stock at a conversion price of $10.00 per share and (iv) 1,201,580 shares of our common stock held in abeyance in connection with a
warrant exercise (due to beneficial ownership limitations).
S-6
Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the
risks described below and in our most recent Annual Report on Form 10-K/A, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in our other Securities and Exchange Commission, or SEC, filings and documents incorporated by reference into
this prospectus supplement and the accompanying prospectus, any amendment or update thereto reflected in our subsequent filings with the SEC, and all of the other information in this prospectus supplement and the accompanying prospectus, including
our financial statements and related notes incorporated by reference into this prospectus supplement and the accompanying prospectus. If any of these risks is realized, our business, financial condition, results of operations and prospects could be
materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial
may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment.
Risks Related to Our Cell Therapy Product Development Efforts
Our activity as a contract manufacturer of biologic-based cosmetics could result in FDA enforcement for reasons
outside of our control, which could disrupt the development of our own product candidates or harm our reputation.
We manufacture a commercial product as a contract manufacturer for a third-party company, Cartessa Aesthetics, LLC, or Cartessa. While we
believe the product we manufacture for Cartessa is intended for cosmetic uses, we (as the contract manufacturer) do not ultimately have control over how the product is marketed. It is possible that the FDA could determine, based on how the product is
marketed (among other considerations), that it is intended for unapproved therapeutic use(s), which could result in the temporary or permanent suspension of manufacturing and/or commercialization of the product and/or a wide range of enforcement
actions, such as warning letters, recall, ‘dear doctor’ letters, and others. If the FDA takes enforcement action against Cartessa or us in connection with this product, it could have an adverse impact on our operations and/or harm our reputation as a
biologics company.
Risks Related to this Offering
We have a limited operating history; we have incurred substantial losses since inception; we expect to continue to
incur losses for the near term.
We have a limited operating history. Since our inception, we have incurred net losses. As
of June 30, 2024, our accumulated deficit was $152,951,151, our cash and cash equivalents was $2,252,247 and our investments held in marketable securities was $12,428,218. Additionally, for the six months ended
June 30, 2024, our net cash used in operating activities was $4,182,945. We expect to incur significant operating losses for the next several years as we complete our clinical trials and
implement our business plan, among others. Because of the numerous risks and uncertainties associated with developing and commercializing pharmaceutical products, we are unable to predict the extent of any future losses or guarantee when, or if,
we will become profitable or cash flow positive. If we never achieve profitability or positive cash flows, or achieve either later than we anticipate, you may lose some or all of your investment in us.
S-7
We will need to obtain a significant amount of financing to complete our clinical trials and implement our business
plan.
Since our inception, we have not generated significant revenues from our operations and have funded our operations through the sale of
our equity securities and debt securities. The implementation of our business plan (as discussed under “Our Company” above), will require the receipt of sufficient equity and/or debt financing to purchase necessary equipment, technology and
materials, fund our clinical trials and other research and development efforts and otherwise fund our operations. We will require significant additional funding to complete our clinical trials using BRTX-100.
We will also require a substantial amount of additional funding to implement our other programs described in “Our Company”, including our metabolic ThermoStem Program and biocosmeceuticals business, and fund general operations. No assurance can be given that the amount of funding that we anticipate may be required for such purposes is correct or that we will be able to accomplish our goals within the
timeframes projected. In addition, no assurance can be given that we will be able to obtain any required financing on commercially reasonable terms or otherwise. In the event we do not obtain the financing required for the above purposes, we may have
to curtail our development, marketing and promotional activities, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations and
liquidate.
We will have broad discretion in how we use the net proceeds of this offering. We may not use these proceeds
effectively, which could affect our results of operations and cause our stock price to decline.
Although we currently intend to use the net proceeds from this offering in the manner described in the section entitled “Use of Proceeds” on page S-13 of this prospectus supplement, we will have considerable discretion in the application of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a
significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. If we do not invest or apply the net
proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.
It is not possible to predict the actual number of shares we will sell under the Sales Agreement, or the gross
proceeds resulting from those sales.
Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement
notice to the Agent at any time throughout the term of the Sales Agreement. The number of shares that are sold through the Agent after delivering a placement notice will fluctuate based on a number of factors, including the market price of the common
stock during the sales period, the limits we set with the Agent in any applicable placement notice, and the demand for our common stock during the sales period. Because the price per share of each share sold will fluctuate during the sales period, it
is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with those sales, if any.
S-8
The common stock offered hereby will be sold in an “at the market offering,” and investors who buy shares at
different times will likely pay different prices.
Investors who purchase shares in this offering at different times will likely pay different prices, and so they may experience different
outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in this
offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.
If you purchase shares of common stock in this offering, you may suffer immediate dilution in the book value of your
investment.
The shares sold in this offering, if any, will be sold from time to time at various prices; however, at the assumed offering price of our
common stock, which is higher than the as adjusted net tangible book value per share of our common stock as of June 30, 2024 after giving effect to this offering, investors purchasing shares of our common stock in this offering will pay a price per
share that exceeds the as adjusted net tangible book value per share as of June 30, 2024. Assuming that an aggregate of 2,316,775 shares of our common stock are sold at an assumed offering price of $1.56 per share, the closing price of our common
stock on Nasdaq on October 31, 2024 for aggregate proceeds of approximately $3,614,170, prior to deducting sales commissions and estimated offering expenses payable by us, new investors in this offering will experience immediate dilution of $0.10 per
share, representing the difference between the assumed offering price per share and our as adjusted net tangible book value per share as of June 30, 2024, after giving effect to this offering. See “Dilution” on page S-14.
You may experience significant dilution as a result of future financings, the exercise of outstanding options or
warrants, the conversion of outstanding preferred stock and the issuance of shares held in abeyance.
In order to raise additional capital, we may in the future offer additional shares of common stock or other securities convertible into
or exchangeable for our common stock, including offerings pursuant to the accompanying prospectus. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater
than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional common stock or other
securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering. In addition, as of the date hereof, there are (i) outstanding warrants to purchase up to
3,951,670 shares of our common stock at a weighted exercise price of $3.68 per share, (ii) outstanding options to purchase up to 3,401,608 shares of our common stock at a weighted exercise price of $2.60 per share, (iii) 1,398,158 shares of Series B
preferred stock convertible into an equal number of shares of common stock at a conversion price of $10.00 per share and (iv) 1,201,580 shares of our common stock held in abeyance in connection with a warrant exercise (due to beneficial ownership
limitations). You may experience significant dilution as a result of the exercise of such options and warrants, the conversion of such preferred stock and the issuance of such shares held in abeyance.
S-9
Shares of common stock eligible for future sale may cause the price of our common stock to decline.
From time to time, certain of our stockholders may be eligible to sell all or some of their restricted common stock by means of ordinary
brokerage transactions in the open market pursuant to Rule 144 promulgated under the Securities Act. In general, pursuant to Rule 144, non-affiliated stockholders may freely sell their respective restricted common stock after holding them for six
months, subject only to the current public information requirement (which no longer applies after a one-year holding period). Of the 6,919,919 shares of common stock outstanding as of October 31, 2024, approximately 82% are held by “non-affiliates,”
all of which are currently freely tradable either because they were issued in a registered offering or because they are saleable in accordance with Rule 144.
Any substantial sale of our common stock pursuant to Rule 144 or pursuant to any resale prospectus may have a material adverse effect on
the market price of our common stock.
S-10
This prospectus supplement, the accompanying prospectus, the documents we have filed with the SEC that are
incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and
Section 21E of the Exchange Act. Forward-looking statements are made based on our management’s expectations and beliefs concerning future events impacting our company and are subject to uncertainties and
factors relating to our operations and economic environment, all of which are difficult to predict and many of which are beyond our control. You can identify these statements from our use of the words “estimate,” “project,” “believe,” “intend,”
“anticipate,” “expect,” “target,” “plan,” “may” and similar expressions. These forward-looking statements may include, among other things:
|
|
●
|
statements relating to projected growth and management’s long-term performance goals;
|
|
|
●
|
statements relating to the anticipated effects on results of operations or our financial condition from expected developments or events;
|
|
|
●
|
statements relating to our business and growth strategies; and
|
|
|
●
|
any other statements which are not historical facts.
|
Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or
achievements, or industry results, to differ materially from our expectations of future results, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements may not be realized due to a
variety of factors, including without limitation:
|
|
●
|
our ability to obtain financing needed to complete our clinical trials and implement our business plan;
|
|
|
●
|
our ability to successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic
lumbar disc disease, as well as our metabolic ThermoStem Program and commercial biocosmeceuticals platform;
|
|
|
●
|
our ability to conduct clinical trials with respect to our products and services;
|
|
●
|
our ability to protect our intellectual property;
|
|
|
●
|
our ability to achieve and sustain profitability of the existing lines of business;
|
|
|
●
|
our ability to attract and retain world-class research and development talent;
|
|
|
●
|
our ability to attract and retain key science, technology and management personnel and to expand our management team;
|
|
|
●
|
the accuracy of estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing;
|
|
|
●
|
business interruptions resulting from geo-political actions, including war and terrorism or disease outbreaks (such as the outbreak of COVID-19);
|
|
|
●
|
our ability to attract and retain customers;
|
|
|
●
|
our ability to navigate through the increasingly complex therapeutic regulatory environment;
|
|
|
●
|
our ability to successfully engage in any new business lines that we pursue;
|
|
|
●
|
risks related to the restatement of our previously issued financial statements;
|
|
|
|
●
|
our ability to develop and commercialize our products and services;
|
|
|
●
|
our ability to enter into agreements to implement our business strategy;
|
S-11
|
|
●
|
the acceptance of our products and services by patients, the medical community and commercial buyers;
|
|
|
●
|
our ability to secure necessary media and reagents, as well as devices, materials and systems,
for our clinical trials and commercial production;
|
|
|
●
|
our manufacturing capabilities to produce our products;
|
|
|
●
|
our ability to obtain brown adipose (fat) tissue in connection with our ThermoStem Program;
|
|
|
●
|
our ability to obtain and maintain an adequate level of product liability insurance;
|
|
|
●
|
our ability to obtain third party reimbursement for our products and services from private and governmental insurers;
|
|
|
●
|
the effects of competition in our market areas;
|
|
|
●
|
our reliance on certain key personnel;
|
|
●
|
our ability to comply with Nasdaq’s listing standards;
|
|
|
|
●
|
further sales or other dilution of our equity, which may adversely affect the market price of our common stock; and
|
|
|
●
|
other factors and risks referred to under “Risk Factors” beginning on page S-7 of this prospectus supplement, the accompanying prospectus and under similar
headings in the documents incorporated by reference herein and therein.
|
You should not place undue reliance on any forward-looking statement. We undertake no obligation to update any forward-looking statement to reflect events
or circumstances after the date of this prospectus supplement or to reflect the occurrence of unanticipated events.
You should rely only on the information contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and any
free writing prospectus that we have authorized for use in connection with this offering. We have not authorized anyone to provide you with different information. The securities offered under this prospectus supplement are not being offered in any
state where the offer is not permitted. You should not assume that the information contained in this prospectus supplement or the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering
is accurate as of any date other than the date on the front of this prospectus supplement or the accompanying prospectus, as applicable, or that any information incorporated by reference into this prospectus supplement or the accompanying prospectus
is accurate as of any date other than the date of the document so incorporated by reference. Unless required by law or regulation, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future
events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.
S-12
We may issue and sell shares of common stock having aggregate gross sales proceeds of up to $3,614,170 from time to time in this
offering, prior to deducting sales agent commissions and estimated offering expenses payable by us. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and
net proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares in this offering, or that in the future we will sell any additional shares that remain available for sale under or fully utilize the
Sales Agreement with the Agent as a source of financing.
We intend to use the net proceeds from this offering, if any, in connection with our clinical trials with respect to BRTX-100, pre-clinical research and development with respect to our ThermoStem Program and for general corporate purposes and working capital. We may also use a portion
of the net proceeds from this offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to do so.
The amounts and timing of these expenditures will depend on a number of factors, such as the timing and progress of our research and
development efforts, regulatory actions affecting our product candidates and our business, demand for our commercial products, technological advances and the competitive environment for our product candidates and commercial products. As of the date
of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. Accordingly, we will retain broad discretion over the use of these proceeds.
S-13
If you invest in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share and the
as adjusted net tangible book value per share after giving effect to this offering. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of outstanding
shares of our common stock. Dilution represents the difference between the portion of the amount per share paid by purchasers of shares in this offering and the as adjusted net tangible book value per share of our common stock immediately after
giving effect to this offering. Our net tangible book value as of June 30, 2024 was approximately $10.1 million, or $1.46 per share of common stock.
After giving effect to the sale of our common stock pursuant to this prospectus supplement and the accompanying prospectus in the aggregate amount of
$3,614,170 at an assumed offering price of $1.56 per share, the last reported sale price of our common stock on Nasdaq on October 31, 2024, and after deducting sales commissions and estimated aggregate offering expenses payable by us, our net
tangible book value as of June 30, 2024 would have been approximately $13.5 million, or $1.46 per share of common stock. This represents no increase in the net tangible book value per share to our existing stockholders and an immediate dilution in
net tangible book value of $0.10 per share to new investors.
The following table illustrates this per share dilution:
|
Assumed offering price per share
|
$
|
1.56
|
||||||
|
Net tangible book value per share as of June 30, 2024
|
$
|
1.46
|
|
|||||
|
Increase per share attributable to this offering
|
$
|
-
|
||||||
|
As adjusted net tangible book value per share as of June 30, 2024, after giving effect to this offering
|
$
|
1.46
|
||||||
|
Dilution per share to new investors purchasing shares in this offering
|
$
|
0.10
|
||||||
The foregoing table and discussion are based on 6,919,919 shares of common stock outstanding as of June 30, 2024 and excludes, as of June 30, 2024, (i)
outstanding warrants to purchase up to 3,952,511 shares of our common stock at a weighted exercise price of $3.85 per share, (ii) outstanding options to purchase up to 3,401,608 shares of our common stock at a weighted exercise price of $2.60 per
share, (iii) 1,398,158 shares of Series B preferred stock convertible into an equal number of shares of common stock at a conversion price of $10.00 per share and (iv) 1,201,580 shares of our common stock held in abeyance in connection with a warrant
exercise (due to beneficial ownership limitations). To the extent that warrants and options are exercised, Series B preferred stock is converted and shares held in abeyance are issued, there may be further dilution to new investors.
S-14
We entered into the Sales Agreement with the Agent. Pursuant to such agreement, this prospectus supplement and the accompanying prospectus, we may issue
and sell from time to time shares of our common stock having an aggregate offering price of up to $3,614,170 through the Agent as our sales agent. Sales of the common stock, if any, will be made by any method permitted by law deemed to be an
“at-the-market offering” as defined in Rule 415 promulgated under the Securities Act, including sales made directly on Nasdaq, the trading market for our common stock, or any other existing trading market in the United States for our common stock,
sales made to or through a market maker other than on an exchange or otherwise, directly to the Agent as principal in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices or in
any other method permitted by law.
If we and the Agent agree on any method of distribution other than sales of shares of our common stock on Nasdaq or another existing trading market in the
United States at market prices, we will file a further prospectus supplement providing all information about such offering as required by Rule 424(b) under the Securities Act.
The Agent will offer our common stock at prevailing market prices subject to the terms and conditions of the Sales Agreement as agreed upon by us and the
Agent. We will designate the number of shares which we desire to sell, the time period during which sales are requested to be made, any limitation on the number of shares that may be sold in one day and any minimum price below which sales may not be
made. Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell on our behalf all of the shares
of common stock requested to be sold by us. We or the Agent may suspend the offering of the common stock being made through the Agent under the Sales Agreement upon proper notice to the other party and pursuant to the terms of the Sales Agreement.
Settlement for sales of common stock will occur on the first business day or such shorter settlement cycle as may be in effect under the Exchange Act from
time to time, following the date on which any sales are made, or on some other date that is agreed upon by us and the Agent in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as
contemplated in this prospectus supplement and the accompanying prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and the Agent may agree upon. There is no arrangement for funds to be
received in an escrow, trust or similar arrangement.
We will pay the Agent a cash commission equal to 3.0% of the gross sales price per share of common stock issued by us and sold by the Agent under the Sales
Agreement. Because there is no minimum offering amount required as a condition to this offering, the actual total offering amount, sales commissions and net proceeds to us, if any, are not determinable at this time. Pursuant to the terms of the Sales
Agreement, we have agreed to pay the Agent a fee not to exceed $35,000 for the reasonable fees and expenses of its legal counsel (excluding any periodic due diligence fees) incurred in connection with entering into the transactions contemplated by
the Sales Agreement. Additionally, pursuant to the terms of the Sales Agreement, we have also agreed to reimburse the Agent $5,000 per due diligence update session conducted in connection with each such date we file our Annual Report on Form 10-K and
our Quarterly Reports on Form 10-Q. We estimate that the total expenses of the offering payable by us, excluding commissions payable to the Agent under the Sales Agreement, will be approximately $150,000. We will disclose in our Annual Reports on
Form 10-K and Quarterly Reports on Form 10-Q, as applicable, the number of shares of our common stock sold through the Agent under the Sales Agreement, the net proceeds to us and the compensation paid by us with respect to sales under the Sales
Agreement during the relevant quarter.
S-15
In connection with the sales of common stock on our behalf, the Agent will be deemed to be an “underwriter” within the meaning of the Securities Act, and
the compensation paid to the Agent will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and contribution to the Agent against certain liabilities, including liabilities under the
Securities Act.
The offering of our shares of common stock pursuant to this prospectus supplement will terminate upon the earlier of (a) the sale of the shares of common
stock pursuant to this prospectus supplement and the accompanying prospectus having an aggregate sales price of $3,614,170, or (b) termination of the Sales Agreement as permitted therein.
To the extent required by Regulation M, the Agent will not engage in any market making activities involving our shares of common stock while the offering
is ongoing under this prospectus supplement and the accompanying prospectus.
From time to time, the Agent and its affiliates may provide in the future various advisory, investment and commercial banking and other services to us and
our affiliates in the ordinary course of business, for which they have received and may continue to receive customary fees and commissions. In addition, in the ordinary course of its various business activities, the Agent and its affiliates may make
or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans) for their own account and for the accounts of their customers. Such
investments and securities activities may involve securities and/or instruments of ours or our affiliates. The Agent or its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such
securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. Except as disclosed in this prospectus supplement and the accompanying prospectus, we have no
present arrangements with the Agent for any further services.
This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions. A copy of the Sales
Agreement is included as an exhibit to our Current Report on Form 8-K that will be filed with the SEC and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus form a part. See
“Where You Can Find More Information” and “Incorporation of Certain Information by Reference.”
S-16
This prospectus supplement and accompanying base prospectus in electronic format may be made available on a website maintained by the Agent and the Agent
may distribute this prospectus supplement electronically.
Transfer Agent
The transfer agent for our common stock is Transhare Corporation.
S-17
The validity of the issuance of the securities to be offered by this prospectus supplement will be passed upon for us by Certilman Balin
Adler & Hyman, LLP, East Meadow, New York. As of November 6, 2024, Certilman Balin Adler & Hyman, LLP owned 41 shares of our common stock. Haynes and Boone, LLP, New York, New York, is acting as counsel to the Agent in connection with this
offering.
The financial statements as of and for the years ended December 31, 2022 and 2023, incorporated by reference into this prospectus
supplement and in the registration statement, have been so incorporated in reliance on the report of Marcum LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in
auditing and accounting.
We have filed a registration statement on Form S-3 with the SEC under the Securities Act. This prospectus supplement and the accompanying
prospectus is part of the registration statement but the registration statement includes and incorporates by reference additional information and exhibits. You can obtain a copy of the registration statement, at prescribed rates, from the SEC for
free at www.sec.gov. The registration statement and the documents referred to below under “Incorporation of Certain Information By Reference” are also available on our website, www.biorestorative.com. The information on the SEC’s website is not part
of this prospectus supplement and the accompanying prospectus, and any references to this website or any other website are inactive textual references only.
We file annual, quarterly and current reports, proxy statements and other information with the SEC. We make
available free of charge on or through our website at www.biorestorative.com, our Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, Current Reports on Form 8-K, amendments to those reports, and other information that we filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such
material with or otherwise furnish it to the SEC.
We have not incorporated by reference into this prospectus supplement or the accompanying prospectus the information on our website,
and you should not consider it to be a part of this prospectus supplement or the accompanying prospectus.
The SEC permits us to “incorporate by reference” the information contained in documents we file with the SEC, which means that we can disclose important
information to you by referring you to those documents rather than by including them in this prospectus supplement and the accompanying prospectus. Information that is incorporated by reference is considered to be part of this prospectus supplement
and the accompanying prospectus and you should read it with the same care that you read this prospectus supplement and the accompanying prospectus. Later information that we file with the SEC will automatically update and supersede the information
that is either contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus, and will be considered to be a part of this prospectus supplement and the accompanying prospectus from the date those
documents are filed. We have filed with the SEC, and incorporate by reference into this prospectus supplement and the accompanying prospectus (Commission File No. 001-37603):
S-18
|
|
●
|
our Annual Report on Form 10-K filed for the year ended December
31, 2023, filed with the SEC on April 1, 2024, as amended by our Annual Report on Form 10-K/A (Amendment No. 1) for the year ended
December 31, 2023, filed with the SEC on June 11, 2024, and our Annual Report on Form 10-K/A (Amendment No. 2) for the year ended
December 31, 2023, filed with the SEC on November 6, 2024;
|
|
●
|
our Quarterly Report on Form 10-Q for the period ended March 31,
2024, filed with the SEC on June 11, 2024;
|
|
|
●
|
our Quarterly Report on Form 10-Q for the period ended June 30,
2024, filed with the SEC on August 13, 2024;
|
|
|
●
|
|
|
|
●
|
|
|
|
●
|
|
|
|
●
|
|
|
|
●
|
the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on November 4, 2021, and any amendment or report filed with the SEC for the purpose of updating the description,
including Exhibit 4.1 to our Annual Report on 10-K, as amended, for the year ended December 31, 2023.
|
We also incorporate by reference into this prospectus supplement all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form
8-K and exhibits filed on such form that are related to such items) that are subsequently filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of the offering of the securities made by
this prospectus supplement. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.
Any statement contained in this prospectus supplement, the accompanying prospectus or in a document incorporated or deemed to be incorporated by reference
into this prospectus supplement or the accompanying prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus supplement or the accompanying prospectus or any subsequently filed document that
is deemed to be incorporated by reference into this prospectus supplement and the accompanying prospectus modifies or supersedes the statement.
S-19
We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, excluding exhibits to
these documents unless the exhibits are specifically incorporated by reference into such documents. You should direct any requests for documents to:
BioRestorative Therapies, Inc.
40 Marcus Drive, Suite One
Melville, New York 11747
(631) 760-8100
Attention: Secretary
S-20
BIORESTORATIVE THERAPIES, INC.
$75,000,000
Common Stock
Preferred Stock
Warrants
Debt Securities
Units
____________________
We may offer, issue and sell, from time to time, in one or more offerings, the securities described in this prospectus. The aggregate initial offering price of all securities
sold under this prospectus by us will not exceed $75,000,000.
This prospectus describes the general terms of our securities and the general manner in which our securities will be offered by us. We will provide the specific terms of these
offerings in supplements to this prospectus. We may authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The applicable prospectus supplement and any related free writing prospectus may also add,
update or change information contained or incorporated by reference in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well
as any documents incorporated by reference, before buying any of the securities being offered.
We may offer securities in amounts, at prices and on terms determined at the time of offering. Our securities may be sold directly to you, through agents, or through
underwriters and dealers. If agents, underwriters or dealers are used to sell our securities, we will name them and describe their compensation in a prospectus supplement. No securities may be sold without delivery of this prospectus and the
applicable prospectus supplement describing the method and terms of the offering of such securities.
Our common stock is listed on the Nasdaq Capital Market under the symbol “BRTX.”
As of February 6, 2023, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was $8,900,824, based on 3,679,847 shares of
common stock outstanding, of which 2,889,878 shares were held by non-affiliates, and a price of $3.08 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on February 6, 2023. Pursuant to General
Instruction I.B.6 of Form S-3, in no event will we sell shares pursuant to this prospectus with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate
market value of our common stock held by non-affiliates is less than $75,000,000. During the 12 calendar months prior to, and including, the date of this prospectus, we have not sold securities pursuant to General Instruction I.B.6 of Form S-3.
____________________
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” on page 3 and contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference in this
prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
This prospectus may not be used to consummate sales of securities unless accompanied by a prospectus supplement.
____________________
The date of this prospectus is February 14, 2023.
TABLE OF CONTENTS
|
Page
|
|
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, referred to as the SEC, using a “shelf”
registration process. Under this shelf registration process, we may from time to time offer and sell any of the securities or any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount not to
exceed $75,000,000.
This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. Such prospectus supplement may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this
prospectus and the applicable prospectus supplement, you should rely on the information in the prospectus supplement. You should read the information in this prospectus, the applicable prospectus supplement, any free writing prospectus that we
authorize for use in connection with this offering and the additional information incorporated by reference herein as provided for under the heading “Incorporation of Certain Information by Reference.”
You should rely only on the information contained or incorporated by reference in this prospectus, any applicable prospectus supplement and any free
writing prospectuses that we authorize for use in connection with this offering. We have not authorized anyone to provide you with different or additional information. If anyone provides you with different or additional information, you should not
rely on it. We are not making an offer to sell the securities in any jurisdiction where the offer or sale is not permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to
make such offer or solicitation. You should not assume that the information contained or incorporated by reference in this prospectus, any prospectus supplement, or any free writing prospectus that we authorize for use in connection with this
offering is accurate or complete as of any date other than the dates of the applicable documents. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates.
This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents
for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the
registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Obtain More Information.” As permitted by the rules
and regulations of the SEC, the registration statement that contains this prospectus includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC’s web
site or at the SEC’s offices described below under the heading “Where You Can Obtain More Information.”
Unless the context of this prospectus indicates otherwise, the terms “BioRestorative,” the “Company,” “we,” “us” or “our” refer to BioRestorative
Therapies, Inc. and its subsidiaries.
1
We are subject to the information requirements of the Securities Exchange Act of 1934, as amended, referred to as the Exchange Act, which means that we are
required to file annual, quarterly and current reports, proxy statements and other information with the SEC, all of which are available at the Public Reference Room of the SEC at 100 F Street, NE, Washington D.C. 20549. You may also obtain copies of
these reports, proxy statements and other information from the Public Reference Room of the SEC, at prescribed rates, by calling 1-800-SEC-0330. The SEC maintains an Internet website at http://www.sec.gov where you can access reports, proxy
statements, information and registration statements, and other information regarding us that we file electronically with the SEC. In addition, we make available, without charge, through our website, www.biorestorative.com, electronic copies of
various filings with the SEC, including copies of Annual Reports on Form 10-K. Information on our website should not be considered a part of this prospectus, and we do not intend to incorporate in this prospectus any information contained on our
website.
The SEC allows us to “incorporate by reference” the information we file with it, which means that we can disclose important information to you by referring
to those documents filed separately with the SEC. The information we incorporate by reference is an important part of this prospectus. We incorporate by reference the documents listed below, except to the extent that any information contained in
those documents is deemed “furnished” in accordance with SEC rules.
|
•
|
|
|
•
|
|
|
•
|
|
|
•
|
|
|
•
|
|
|
•
|
|
|
•
|
|
|
•
|
The description of our common stock contained in our registration statement on Form 8-A filed
with the SEC on November 4, 2021 (File No. 001-37603), and any amendment or report filed with the SEC for the purpose of updating the description.
|
We also incorporate by reference additional documents that we will file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act
prior to the termination of the offering under this prospectus. Those documents include periodic reports such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements on Schedule DEF
14A.
2
Any statement contained in a document that is incorporated by reference will be modified or superseded for all purposes to the extent that a statement
contained in this prospectus, any prospectus supplement or any free writing prospectus that we authorize for use in connection with this offering modifies or is contrary to that previous statement. Any statement so modified or superseded will not be
deemed a part of this prospectus or any prospectus supplement except as so modified or superseded.
Documents which we incorporate by reference are available from us without charge, excluding all exhibits, unless we have specifically incorporated by
reference an exhibit in this prospectus. You may obtain documents incorporated by reference in this prospectus by requesting them in writing or by telephone from us at:
BioRestorative Therapies, Inc.
40 Marcus Drive, Suite One
Melville, New York 11747
(631) 760-8100
Attention: Secretary
3
An investment in our securities involves a high degree of risk. Prior to making a decision about investing in our securities, you
should consider carefully the specific risk factors discussed in the section entitled “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Factors That May Affect Future Results and Financial Condition” contained
in our most recent Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC, and which is incorporated in this prospectus by reference in its entirety, as well as any amendment or updates to our risk factors reflected in
subsequent filings with the SEC, including any prospectus supplement hereto. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as
immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be
materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your investment. Please also refer to the section below entitled “Special
Cautionary Note Regarding Forward-Looking Statements.”
Some of the statements in or incorporated by reference into this prospectus contain “forward-looking statements.” Forward-looking statements are made based on our
management’s expectations and beliefs concerning future events impacting our company and are subject to uncertainties and factors relating to our operations and economic environment, all of which are difficult to predict and many of which are
beyond our control. You can identify these statements from our use of the words “estimate,” “project,” “believe,” “intend,” “anticipate,” “expect,” “target,” “plan,” “may” and similar expressions. These forward-looking statements may include, among
other things:
|
|
●
|
statements relating to projected growth and management’s long-term performance goals;
|
|
|
●
|
statements relating to the anticipated effects on results of operations or our financial condition from expected developments or events;
|
|
|
●
|
statements relating to our business and growth strategies; and
|
|
|
●
|
any other statements which are not historical facts.
|
Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or
industry results, to differ materially from our expectations of future results, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements may not be realized due to a variety of factors,
including without limitation:
|
|
●
|
our current and anticipated cash needs and our need for additional financing;
|
|
|
●
|
federal, state and foreign regulatory requirements;
|
|
|
●
|
our ability to conduct clinical trials with respect to our products and services;
|
|
|
●
|
our ability to develop and commercialize our products and services;
|
|
|
●
|
our ability to enter into agreements to implement our business strategy;
|
4
|
|
●
|
the acceptance of our products and services by patients and the medical community;
|
|
|
●
|
our ability to secure necessary media and reagents, as well as devices, materials and systems, for our clinical trials and commercial production;
|
|
|
●
|
our manufacturing capabilities to produce our products;
|
|
|
●
|
our ability to obtain brown adipose (fat) tissue in connection with our ThermoStem Program;
|
|
|
●
|
our ability to protect our intellectual property;
|
|
|
●
|
our ability to obtain and maintain an adequate level of product liability insurance;
|
|
|
●
|
our ability to obtain third party reimbursement for our products and services from private and governmental insurers;
|
|
|
●
|
the effects of competition in our market areas;
|
|
|
●
|
our reliance on certain key personnel;
|
|
|
●
|
further sales or other dilution of our equity, which may adversely affect the market price of our securities; and
|
|
|
●
|
other factors and risks referred to under “Risk Factors” on page 4 of this prospectus.
|
You should not place undue reliance on any forward-looking statement. We undertake no obligation to update any forward-looking statement to reflect events or circumstances
after the date of this prospectus or to reflect the occurrence of unanticipated events.
We develop therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
|
|
●
|
Disc/Spine Program (brtxDisc). Our lead cell therapy
candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow.
We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an
outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has
not been alleviated by non-surgical procedures and who potentially face the prospect of surgery. We have received authorization from the FDA to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have commenced such clinical trial through the execution of a CRO agreement with PRC Clinical, the
execution of clinical trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the expansion of our laboratory to include capabilities for clinical production. In March
2022, a United States patent related to BRTX-100 was issued. We have been granted excusive license rights with regard to the patent.
|
5
|
|
●
|
Metabolic Program (ThermoStem). We are developing a cell-based
therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue, or BAT. We refer to this as our ThermoStem Program. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may
be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. Patents related to the ThermoStem Program have been issued in the United States and other jurisdictions.
|
We have also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs (and other parts of
the body). We anticipate that FDA approval or clearance will be necessary for this device prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to BRTX-100.
The patents and patent applications for the Disc/Spine Program, the ThermoStem Program and the
curved needle device are listed under “Business - Technology; Research and Development” in Part I of our Annual Report on Form 10-K for the year ended December 31, 2021 incorporated herein by reference.
We are a Nevada corporation. Our headquarters are located at 40 Marcus Drive, Suite One, Melville, New York 11747. Our telephone
number is (631) 760-8100. We maintain certain information on our website at www.biorestorative.com. The information on our website is not (and should not be considered) part of this prospectus and is not incorporated into this prospectus by
reference.
Unless we indicate a different use in an accompanying prospectus supplement, the net proceeds from our sale of the offered securities will be used for
general corporate purposes and working capital, including in connection with our clinical trials with respect to BRTX-100, pre-clinical research and development with respect to our ThermoStem Program and other business initiatives.
The applicable prospectus supplement will provide more details on the use of proceeds of any specific offering.
This prospectus contains summary descriptions of the common stock, preferred stock, warrants, debt securities and units that we may offer from time to time. These summary
descriptions do not purport to be complete and are subject to, and qualified in their entirety by reference to, the more complete descriptions thereof set forth in our amended and restated articles of incorporation, which we refer to as our charter,
and our bylaws, each as amended to date. The applicable prospectus supplement may add, update or change the terms and conditions of the securities as described in this prospectus.
6
Authorization
Our authorized capital stock consists of 95,000,000 shares of capital stock. We are authorized to issue 75,000,000 shares of common stock, par value $0.0001 per share, and
20,000,000 shares of preferred stock, par value $0.01 per share.
As of February 6, 2023, there were 3,679,847 shares of common stock issued and outstanding and 1,543,158 shares of Series B preferred stock issued and outstanding.
Common Stock
Dividend Rights. Subject to preferences that may be applicable to
any shares of our preferred stock that may be issued, the holders of our common stock are entitled to share ratably in such dividends as may be declared by our Board of Directors out of funds legally available therefor.
Voting Rights. Each share of our common stock entitles its holder
to one vote in the election of directors as well as all other matters to be voted on by stockholders.
No Preemptive Rights. Holders of our common stock do not have any
preemptive rights to subscribe for additional shares on a pro rata basis or otherwise when additional shares are offered for sale by us.
Liquidation Rights. Subject to preferences that may be applicable
to any shares of our preferred stock that may be issued, in the event of our liquidation, dissolution or winding up, the holders of our common stock would be entitled to receive, pro rata, after payment of all of our debts and liabilities, all of
our remaining assets available for distribution.
Other Rights. Holders of our common stock have no preferences or
conversion or exchange rights. Shares of our common stock will not be liable for further calls or assessments by us and are not subject to redemption.
Preferred Stock
Our board of directors has the authority, without further action by our stockholders, to issue from time to time the authorized preferred stock in one or
more series, and to fix the number of shares, designations, preferences, powers, and other rights and qualifications, limitations or restrictions as our board of directors may authorize, including:
|
•
|
the distinctive designation of each series and the number of shares that will constitute the series;
|
|
•
|
the voting rights, if any, of shares of the series and the terms and conditions of the voting rights;
|
7
|
•
|
the dividend rate on the shares of the series, the dates on which dividends are payable, any restriction, limitation or condition upon the payment of dividends, whether dividends will be
cumulative, and the dates from and after which dividends shall accumulate;
|
|
•
|
the prices at which, and the terms and conditions on which, the shares of the series may be redeemed, if the shares are redeemable;
|
|
•
|
the terms and conditions of a sinking or purchase fund for the purchase or redemption of shares of the series, if such a fund is provided;
|
|
•
|
any preferential amount payable upon shares of the series in the event of our liquidation, dissolution or winding up, or upon the distribution of any of our assets; and
|
|
•
|
the prices or rates of conversion or exchange at which, and the terms and conditions on which, the shares of the series may be converted or exchanged into other securities, if the shares
are convertible or exchangeable.
|
Depending upon the rights prescribed for a series of preferred stock, the issuance of preferred stock could have an adverse effect on the voting power of
the holders of common stock and could adversely affect holders of common stock by delaying or preventing a change in control, making removal of our present management more difficult or imposing restrictions upon the payment of dividends and other
distributions to the holders of common stock.
The particular terms of any series of preferred stock, and the transfer agent and registrar for that series, will be described in a prospectus supplement.
Warrants
We may offer to sell warrants from time to time. If we do so, we will describe the specific terms of the warrants in a prospectus supplement. In particular, we may issue
warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may also issue warrants independently or together with other securities and the warrants may be attached to or separate from those securities.
We will evidence each series of warrants by warrant certificates that we will issue under a separate agreement. We will enter into the warrant agreement with a warrant agent.
We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants.
We will describe in the applicable prospectus supplement the terms of the series of warrants, including:
|
•
|
the offering price and aggregate number of warrants offered;
|
|
•
|
the currency for which the warrants may be purchased;
|
8
|
•
|
if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each
principal amount of such security;
|
|
•
|
if applicable, the date on and after which the warrants and the related securities will be separately transferable;
|
|
•
|
in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency
in which, this principal amount of debt securities may be purchased upon such exercise;
|
|
•
|
in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon
the exercise of one warrant and the price at which these shares may be purchased upon such exercise;
|
|
•
|
the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;
|
|
•
|
the terms of any rights to redeem or call the warrants;
|
|
•
|
any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;
|
|
•
|
the dates on which the right to exercise the warrants will commence and expire;
|
|
•
|
the manner in which the warrant agreement and warrants may be modified;
|
|
•
|
certain United States federal income tax consequences of holding or exercising the warrants;
|
|
•
|
the terms of the securities issuable upon exercise of the warrants; and
|
|
•
|
any other specific material terms, preferences, rights or limitations of or restrictions on the warrants.
|
Debt Securities
The following is a description of the material features, terms and provisions of debt securities that we may offer. This summary does not purport to be exhaustive and may not
contain all the information that is important to you. Therefore, you should read the applicable prospectus supplement relating to those debt securities and any other offering materials that we may provide.
9
We may issue debt securities from time to time in one or more series. We may issue senior debt securities or subordinated debt securities under separate indentures, which may
be supplemented or amended from time to time. Senior debt securities would be issued under a senior indenture and subordinated debt securities would be issued under a subordinated indenture. The senior debt indenture and subordinated debt indenture
are referred to individually in this prospectus as the indenture, and collectively as the indentures.
The particular terms of a series of debt securities will be described in a prospectus supplement relating to such series of debt securities. The indentures will be subject to
and governed by the Trust Indenture Act of 1939, as amended, and may be supplemented or amended from time to time following their execution. Unless otherwise stated in the applicable prospectus supplement, we will not be limited in the amount of debt
securities that we may issue and neither the senior debt securities nor the subordinated debt securities will be secured by any of our property or assets. Thus, by owning debt securities, you are one of our unsecured creditors.
The indentures, and any supplemental indentures, will contain the full legal text of the matters described in this section of the prospectus. Because this section is a summary,
it does not describe every aspect of the debt securities or any applicable indentures or supplemental indenture. This summary is therefore subject to and is qualified in its entirety by reference to all the provisions of any applicable indenture or
supplemental indenture, including any definitions of terms used in such indenture. Your rights will be defined by the terms of any applicable indenture or supplemental indenture, not the summary provided herein. This summary is also subject to and
qualified by reference to the description of the particular terms of a particular series of debt securities described in the applicable prospectus supplement or supplements.
The debt securities may be denominated and payable in U.S. dollars. We may also issue debt securities, from time to time, with the principal amount, interest or other amounts
payable on any relevant payment date to be determined by reference to one or more currency exchange rates, securities or baskets of securities, commodity prices, indices or any other financial, economic or other measure or instrument, including the
occurrence or non-occurrence of any event or circumstance. In addition, we may issue debt securities as part of any units issued by us. All references in this prospectus or any prospectus supplement to other amounts will include premiums, if any,
other cash amounts payable under the applicable indenture, and the delivery of securities or baskets of securities under the terms of the debt securities. Debt securities may bear interest at a fixed rate, which may be zero, or a floating rate.
We will set forth in the applicable prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable for our preferred
stock, common stock or other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our preferred
stock, common stock or other securities that holders of the series of debt securities receive would be subject to adjustment.
The applicable prospectus supplement will describe the debt securities and the price or prices at which we will offer the debt securities. The description will, to the extent
applicable, include:
10
|
•
|
the title and form of the debt securities;
|
|
•
|
the ranking of the debt securities as compared to other debt;
|
|
•
|
the aggregate principal amount of the debt securities or the series of which they are a part;
|
|
•
|
the person or persons to whom any principal or interest on a debt security of the series will be paid;
|
|
•
|
the date or dates on which we must repay the principal;
|
|
•
|
the rate or rates at which the debt securities will bear interest;
|
|
•
|
the date or dates from which interest will accrue, and the dates on which we must pay interest;
|
|
•
|
the place or places where we must pay the principal and any premium or interest on the debt securities;
|
|
•
|
the terms and conditions on which the debt securities may be convertible into other securities;
|
|
•
|
whether the debt securities are entitled to the benefit of any sinking fund;
|
|
•
|
the identity of the trustee;
|
|
•
|
the terms and conditions on which we may redeem any debt security, if at all;
|
|
•
|
any obligation to redeem or purchase any debt securities, and the terms and conditions on which we must do so;
|
|
•
|
the denominations in which we may issue the debt securities;
|
|
•
|
the manner in which we will determine the amount of principal of or any premium or interest on the debt securities;
|
|
•
|
the currency in which we will pay the principal of and any premium or interest on the debt securities;
|
|
•
|
the principal amount of the debt securities that we will pay upon declaration of acceleration of their maturity;
|
|
•
|
the amount that will be deemed to be the principal amount for any purpose, including the principal amount that will be due and payable upon any maturity or that will
be deemed to be outstanding as of any date;
|
11
|
•
|
whether the debt securities are defeasible and the terms of such defeasance; and
|
|
•
|
any addition to or change in the events of default applicable to the debt securities and any change in the right of the trustee or the holders to declare the
principal amount of any of the debt securities due and payable.
|
Some of the debt securities may be issued as original issue discount debt securities. Original issue discount securities bear no interest or bear interest at below market rates
and will be sold at a discount below their stated principal amount. A prospectus supplement relating to an issue of original issue discount securities will contain information relating to United States federal income tax, accounting, and other
special considerations applicable to original issue discount securities.
Units
We may issue units comprised of one or more of the other securities described in this prospectus or any prospectus supplement in any combination. Each unit will be issued so
that the holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the unit. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held
or transferred separately, at any time or at any times before a specified date or upon the occurrence of a specified event or occurrence.
The applicable prospectus supplement will describe:
|
|
•
|
the designation and the terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or
transferred separately;
|
|
|
|
|
|
|
•
|
any unit agreement under which the units will be issued;
|
|
|
|
|
|
|
•
|
any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and
|
|
|
|
|
|
|
•
|
whether the units will be issued in fully registered or global form.
|
Certain Provisions Having Potential Anti-Takeover Effects
General. The following is a summary of the material provisions of
the Nevada Revised Statues, which we refer to as the NRS, and our charter and bylaws that address matters of corporate governance and the rights of stockholders. Certain of these provisions may delay or prevent takeover attempts not first approved
by our Board of Directors (including takeovers which certain stockholders may deem to be in their best interests). These provisions also could delay or frustrate the removal of incumbent directors or the assumption of control by stockholders. The
primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of our company. All references to the charter and bylaws are to our charter and bylaws in effect on the date of this
prospectus.
12
Combinations with Interested Stockholder. Sections 78.411-78.444,
inclusive, of the NRS contain provisions governing combinations with an interested stockholder. For purposes of the NRS, “combinations” include: (i) any merger or consolidation with any interested stockholder, (ii) any sale, lease, exchange,
mortgage, pledge, transfer or other disposition to any interested stockholder of corporate assets with an aggregate market value equal to more than 5% of the aggregate market value of the corporation’s consolidated assets, more than 5% of the
aggregate market value of outstanding shares of the corporation or more than 10% of the earning power or net income of the corporation, (iii) the issuance to any interested stockholder of voting shares (except pursuant to a share dividend or
similar proportionate distribution) with an aggregate market value equal to 5% or more of the aggregate market value of all the outstanding shares of the corporation, (iv) the adoption of the dissolution of the corporation if proposed by or on
behalf of any interested stockholder, (v) any reclassification of securities, recapitalization or corporate reorganization that will have the effect of increasing the proportionate share of the corporation’s outstanding voting shares held by any
interested stockholder and (vi) any receipt by the interested stockholder of the benefit (except proportionately as a stockholder) of any loan, advance, guarantee, pledge or other financial assistance. For purposes of the NRS, an “interested
stockholder” is defined to include any beneficial owner of more than 10% of any class of the voting securities of a Nevada corporation and any person who is an affiliate or associate of the corporation and was at any time during the preceding
two years the beneficial owner of more than 10% of any class of the voting securities of the Nevada corporation.
Subject to certain exceptions, the provisions of the NRS statute governing combinations with interested stockholders provide that a Nevada corporation may not engage in a
combination with an interested stockholder for two years after the date that the person first became an interested stockholder unless the combination or the transaction by which the person first became an interested stockholder is approved by the
Board of Directors before the person first became an interested stockholder, or unless the combination is approved by the Board of Directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder,
its affiliates and associates.
Control Share Acquisitions. The NRS also contains a “control share acquisitions statute.” If applicable to a Nevada corporation this statute restricts the voting rights of certain stockholders referred to as “acquiring persons,” that acquire or offer
to acquire ownership of a “controlling interest” in the outstanding voting stock of an “issuing corporation.” For purposes of these provisions, a “controlling interest” means with certain exceptions the ownership of outstanding voting stock
sufficient to enable the acquiring person to exercise one-fifth or more but less than one-third, one-third or more but less than a majority, or a majority or more of all voting power in the election of directors; “issuing corporation” means a
Nevada corporation that has 200 or more stockholders of record, at least 100 of whom have addresses in Nevada appearing on the stock ledger of the corporation at all times during the 90 days immediately preceding such date, and which does business
in Nevada directly or through an affiliated corporation. The voting rights of an acquiring person in the affected shares will be restored only if such restoration is approved by the holders of a majority of the voting power of the corporation. The
NRS allows a corporation to “opt-out” of the control share acquisitions statute by providing in such corporation’s articles of incorporation or bylaws that the control share acquisitions statute does not apply to the corporation or to an
acquisition of a controlling interest specifically by types of existing or future stockholders, whether or not identified. The Company has not opted out of this statute.
13
Authorized But Unissued Shares. Nevada law does not require
stockholder approval for any issuance of authorized shares. Authorized but unissued shares may be used for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate
acquisitions. One of the effects of the existence of authorized but unissued shares may be to enable our Board of Directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an
attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive the stockholders of opportunities to sell their shares of common stock at
prices higher than prevailing market prices.
Preferred Stock. Under the terms of our charter, our Board of
Directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our Board of Directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights,
dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing our Board of Directors to issue preferred stock and determine its rights and preferences is to
provide flexibility and eliminate delays associated with a stockholder vote on specific issues. However, the ability of our Board of Directors to issue preferred stock and determine its rights and preferences may have the effect of delaying or
preventing a change in control, as described above under “Description of Securities We May Offer — Preferred Stock.”
Classified Board. We have a classified Board of Directors
consisting of three classes of directors. A classified board is one in which a certain number, but not all, of the directors are elected on a rotating basis each year. This method of electing directors makes changes in the composition of our Board
more difficult, and thus a potential change in control may be a lengthier process. The existence of our classified Board reduces the possibility that a third party could effect an unsolicited change in control of our Board. Since our classified
Board will increase the amount of time required for a takeover bidder to obtain control of us without the cooperation of the Board, even if the takeover bidder were to acquire a majority of our outstanding common stock, the existence of our
classified Board could tend to discourage certain tender offers which stockholders might feel would be in their best interests. Our classified Board will likely allow management, if confronted by a proposal from a third party who has acquired a
block of our common stock, sufficient time to review the proposal and appropriate alternatives to the proposal and to attempt to negotiate a better transaction, if possible, for our stockholders.
Special Meetings of Stockholders. Our bylaws provide that special
meetings of stockholders may be called only by our Board of Directors or the Chairman of the Board.
14
Filling Vacancies. Vacancies occurring in our Board of Directors and
newly created directorships resulting from an increase in the authorized number of directors may be filled by a majority of the remaining directors, even if less than a quorum.
Removal of Directors by Stockholders. Under the terms of our
charter, stockholders may remove directors with or without cause with the affirmative vote of holders of 75% of the voting power of all of the then-outstanding shares of our capital stock then entitled to vote at an election of directors, voting
together as a single class.
Amendment of Bylaws. Our bylaws may be amended by our Board of
Directors or by the holders of at least 75% of the voting power of our company.
Amendment of Certain Charter Provisions. Under the terms of our
charter, amending certain charter provisions requires the affirmative vote of the holders of at least 75% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class.
The provisions subject to such heightened requirement include those relating to stockholder action by written consent, the calling of special meetings, board classification, the filling of board vacancies, the removal of directors and the ability
to amend our bylaws, among others.
Advance Notification of Stockholder Nominations and Proposals. Our
bylaws establish advance notice procedures with respect to the nomination of persons for election as directors, other than nominations made by or at the direction of our Board of Directors, and stockholder proposals for business.
Stockholder Nominees; Stockholder Proposals.
In order for a stockholder to nominate a candidate for director at, or bring any business before, an annual meeting of stockholders, under our bylaws, timely notice of the
nomination or business must be received by us in advance of the meeting. To be timely, a stockholder’s notice must be delivered to or mailed and received by our Secretary at our principal executive offices not less than 90 days nor more than 120 days
prior to the one-year anniversary of the date on which we first mailed the proxy materials for the preceding year’s annual meeting of stockholders; provided, however, that if the meeting is convened more than 30 days prior to or delayed more than 60
days after the anniversary of the preceding year’s annual meeting, to be timely a stockholder’s notice must be received not earlier than the close of business on the 120th day prior to the date of such annual meeting and not later than the close of
business on the later of the 90th day prior to the date of such annual meeting or, if the first public announcement of the date of such annual meeting is less than 100 days prior to the date of such annual meeting, the 10th day following the day on
which public announcement of the date of such meeting is first made by us.
The stockholder sending the notice of nomination or proposed business must describe various matters, including the following:
15
|
|
●
|
as to each person whom the stockholder proposes to nominate for election as a director, all information relating to such person as would be required to be disclosed in solicitations of
proxies for election of such nominee as a director pursuant to Regulation 14A under the Exchange Act;
|
|
|
|
|
|
|
●
|
(i) the name and address of such stockholder, as they appear on our books and of such beneficial owner or Control Person (as defined in our bylaws), if any, (ii) the number of our shares
which are, directly or indirectly, owned beneficially and of record by such stockholder and such beneficial owner or Control Person, if any (iii) a representation that the stockholder intends to appear at the meeting in person or by proxy to
submit the business specified in such notice, (iv) if the notice relates to any business other than a nomination of director(s), a brief description of the business desired to be brought before the meeting, including the complete text of any
resolutions proposed for consideration, and the reasons for conducting such business at the meeting, (v) any direct or indirect personal or other interest of the stockholder in the business to be submitted, (vi) a description of any
agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder’s notice by, or
on behalf of, such stockholder or beneficial owner and by any Control Person or any other person acting in concert with any of the foregoing, the effect or intent of which is to mitigate loss, manage risk or benefit from changes in the share
price of any class of our stock, or maintain, increase or decrease the voting power of the stockholder or beneficial owner with respect to shares of our stock, and a representation that the stockholder will notify us in writing within five
business days after the record date for such meeting of any such agreement, arrangement or understanding in effect as of the record date for the meeting, (vii) a representation whether the stockholder or the beneficial owner, if any, and any
Control Person will engage in a solicitation with respect to the nomination or business and, if so, the name of each participant (as defined in Item 4 of Schedule 14A under the Securities Exchange Act of 1934) in such solicitation and whether
such person intends or is part of a group which intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of our outstanding stock required to approve or adopt the business to be proposed (in person or by
proxy) by the stockholder and (viii) any other information relating to such stockholder, beneficial owner or Control Person, if any, that would be required to be disclosed in a proxy statement and form of proxy or other filings required to be
made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to Section 14 of the Securities Exchange Act of 1934 and the rules and regulations
promulgated thereunder.
|
These provisions are intended to enhance the likelihood of continuity and stability in the composition of the Board and in policies formulated by the Board and to discourage
certain types of transactions that may involve an actual or threatened change of control of our company. These provisions are designed to reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of
all of our outstanding shares or an unsolicited proposal for the restructuring or sale of all or part of our company.
16
Limitations on Director Liability
Our charter provides that our directors shall generally not be liable to us or any of our stockholders for damages for breach of duty as a director. This provision will
eliminate such liability except for (i) any breach of the director’s duty of loyalty to us or to our stockholders, (ii) acts and omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) liability for
unlawful payment of dividends or unlawful stock purchases or redemptions in violation of the NRS, and (iv) any transaction from which the director derived an improper personal benefit.
Indemnification of Directors and Officers
Section 78.7502(1) of the NRS provides that a corporation may, and our charter and bylaws provide that we shall, indemnify any person who was or is a party or is threatened
to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, or an Action, by reason of the fact that he is or was our director, officer, employee or agent or is or
was serving at our request in such capacity in another corporation, partnership, joint venture, trust or other enterprise, or the Indemnified Party, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to our best interests, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful; provided, however, no indemnification shall be made in respect of any Actions by or in our right if the Indemnified Party shall have been adjudged by a court of competent
jurisdiction, after exhaustion of any appeals, to be liable to us, unless and only to the extent that the court shall determine that, despite the adjudication of liability but in view of all circumstances, such person is fairly and reasonably
entitled to indemnity.
Under the NRS, the directors have a fiduciary duty to us that is not eliminated by this provision of our charter and, in appropriate circumstances, equitable remedies such as
injunctive or other forms of non-monetary relief will remain available. In addition, each director will continue to be subject to liability under the NRS for breach of the director’s duty of loyalty to us for acts or omissions which are found by a
court of competent jurisdiction to not be in good faith or involve intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases
or redemptions that are prohibited by the NRS. This provision also does not affect the directors’ responsibilities under any other laws, such as the federal securities laws or state or federal environmental laws.
Furthermore, Section 78.7502(3) of the NRS provides that determination of an Indemnified Party’s eligibility for indemnification by us shall be made on a case-by-case basis
by: (i) the stockholders; (ii) the board of directors by a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding; (iii) independent legal counsel’s written opinion if: (1) a majority vote of a quorum
consisting of directors who were not parties to the action, suit or proceeding so orders; or (2) a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained.
17
Lastly, Section 78.752(1) of the NRS empowers a corporation to purchase and maintain insurance or make other financial arrangements with respect to liability arising out of
the actions or omissions of directors, officers, employees or agents in their capacity or status as such, whether or not the corporation has the authority to indemnify him against such liability.
Our charter provides that, to the fullest extent permitted by the NRS, no director or officer shall be personally liable to us or to our stockholders for monetary damages for
breach of fiduciary duty as a director or an officer, except to the extent that such exemption from liability or limitation thereof is not permitted under the NRS currently in effect or as the same may be amended. If the NRS is amended to further
eliminate or limit or authorize corporate action to further eliminate or limit the liability of directors or officers, the liability of our directors and officers shall be eliminated or limited to the fullest extent permitted by the NRS, as so
amended from time to time. No repeal or modification of this provision of our charter will apply to or have any effect on the liability or alleged liability of any of our directors or officers for or with respect to any acts or omissions of such
directors or officers occurring prior to such repeal or modification.
Our bylaws provide that we will indemnify and hold harmless any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative, in such manner, under such circumstances and to the fullest extent permitted by our charter and the NRS.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons under the provisions discussed
above or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Transfer Agent
The transfer agent for our common stock is Transhare Corporation.
We may use this prospectus, any applicable prospectus supplement and any related free writing prospectus that we authorize for use in connection with this
offering to sell our securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell our securities (1) through one or more underwriters or dealers, (2)
through one or more agents, and/or (3) directly to one or more purchasers. We may distribute our securities from time to time in one or more transactions at:
|
•
|
a fixed price or prices, which may be changed;
|
|
•
|
market prices prevailing at the time of sale;
|
|
•
|
prices related to the prevailing market prices;
|
18
|
•
|
varying prices determined at the time of sale; or
|
|
•
|
negotiated prices.
|
We may solicit directly offers to purchase the securities being offered by this prospectus. We may also designate agents to solicit offers to purchase our
securities from time to time. We will name in a prospectus supplement any underwriter, dealer or agent involved in the offer or sale of our securities and describe any commissions payable by us to these agents in the applicable prospectus supplement.
Unless otherwise indicated in the applicable prospectus supplement, these agents will be acting on a best efforts basis for the period of their appointment. The agents may be customers of, or may engage in transactions with or perform services for,
us in the ordinary course of business.
We may also sell equity securities covered by this registration statement in an “at the market” offering as defined in Rule 415(a)(4) under the Securities Act. Such offering
may be made into an existing trading market for such securities in transactions at other than a fixed price on or through the facilities of the Nasdaq Capital Market or any other securities exchange or quotation or trading service on which such
securities may be listed, quoted or traded at the time of sale. Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent.
If we utilize a dealer in the sale of the securities being offered by this prospectus, we will sell our securities to the dealer, as principal. The dealer
may then resell our securities to the public at varying prices to be determined by the dealer at the time of resale.
If we utilize an underwriter in the sale of our securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter
at the time of sale and we will provide the name of any underwriter in the prospectus supplement which the underwriter will use to make resales of our securities to the public. In connection with the sale of our securities, we, or the purchasers of
our securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell our securities to or through dealers, and the underwriter may compensate those
dealers in the form of discounts, concessions or commissions.
With respect to underwritten public offerings, negotiated transactions and block trades, we will provide in the applicable prospectus supplement any
compensation we pay to underwriters, dealers or agents in connection with the offering of our securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating
in the distribution of our securities may be deemed to be underwriters within the meaning of the Securities Act and any discounts and commissions received by them and any profit realized by them on resale of our securities may be deemed to be
underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in
respect thereof.
19
Our common stock is listed for trading on the Nasdaq Capital Market. We may elect to list any other security we offer on an exchange, but we are not obligated to do so. To
facilitate the offering of our securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of our securities. This may include over-allotments or short sales of our
securities, which involve the sale by persons participating in the offering of more securities than we sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or
by exercising their over-allotment option. In addition, these persons may stabilize or maintain the price of our securities by bidding for or purchasing our securities in the open market or by imposing penalty bids, whereby selling concessions
allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of our
securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time.
The underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course of their business.
In order to comply with the securities laws of certain states, if applicable, the securities offered by this prospectus may be sold in these jurisdictions
only through registered or licensed brokers or dealers. In addition, in certain states, the securities offered by this prospectus may not be sold unless such securities have been registered or qualified for sale in these states or an exemption from
registration or qualification is available.
Except as otherwise provided in any prospectus supplement, the validity of the issuance of the securities to be offered by this prospectus will be passed
upon for us by Certilman Balin Adler & Hyman, LLP, East Meadow, New York. As of February 6, 2023, members of Certilman Balin Adler & Hyman, LLP owned 41 shares of our common stock. If legal matters in connection with offerings made pursuant
to this prospectus are passed upon by counsel for underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering.
Our consolidated financial statements as of December 31, 2021 and 2020 and for the years then ended appearing in our Annual Report on Form 10-K for the
year ended December 31, 2021 have been incorporated by reference in this prospectus in reliance upon the report of Friedman LLP, an independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm
as experts in accounting and auditing.
20
Up to $3,614,170
Common Stock
____________________________
PROSPECTUS SUPPLEMENT
____________________________
Rodman & Renshaw LLC
____________________________
November 6, 2024